Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4049/jimmunol.2100131 http://scihub22266oqcxt.onion/10.4049/jimmunol.2100131 34417260!ä!34417260 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Immunol 2021 ; 207 (6): 1591-1598 Nephropedia Template TP {{tp|p=34417260|t=2021. SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis |pdf=|usr=}}{{34417260}} gab.com Text SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis JO: J Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34417260 #FOAvip COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. In this study, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor through the upregulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. This new evidence pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target. Twit Text FOAVip SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis ????J Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34417260 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34417260 #FOAvip English Wikipedia <ref>{{Cite pmid|34417260}}</ref> SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis #MMPMID34417260 Alves I; Vicente MM; Gaifem J; Fernandes A; Dias AM; Rodrigues CS; Oliveira JC; Seixas N; Malheiro L; Abreu MA; Sarmento E Castro R; Pinho SS J Immunol 2021[Sep]; 207 (6): 1591-1598 PMID34417260show ga COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. In this study, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor through the upregulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. This new evidence pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target. |*COVID-19[MESH] |*SARS-CoV-2[MESH] |Humans[MESH] |Polysaccharides[MESH] |Receptors, Virus[MESH]SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at D(epmc).pdf DeepDyve Pubget Overpricing